Practical applications of vitreous imaging for the treatment of vitreous opacities with YAG vitreolysis.


Journal

International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 30 01 2022
accepted: 08 06 2023
medline: 18 9 2023
pubmed: 4 7 2023
entrez: 4 7 2023
Statut: ppublish

Résumé

To demonstrate the methodology and efficacy of using scanning laser ophthalmoscopy (SLO) and dynamic optical coherence tomography (OCT) to identify and treat symptomatic vitreous floaters using yttrium-aluminum garnet laser vitreolysis (YLV). This is a case series highlighted from a cross sectional retrospective study conducted at the Vitreous Retina Macula Specialists of Toronto. Forty eyes from thirty-five patients were treated with YLV between November 2018 and December 2020 for symptomatic floaters and imaged with SLO and dynamic OCT. Patients were re-treated with YLV if they reported ongoing significant vision symptoms during follow-up which correlated to visible opacities on exam and or imaging. Three cases will be highlighted to present the practical applications of SLO and dynamic OCT imaging for YLV treatment. Forty treated eyes were enrolled in this study, with twenty-six eyes (65%) requiring at least one repeat YLV treatment following the first treatment due to ongoing symptomatic floaters. Following the first YLV, there was a significant improvement in overall mean best corrected visual acuity compared to before treatment (0.11 ± 0.20 LogMAR units vs. 0.14 ± 0.20 LogMAR units, p = 0.02 (paired t test)). Case 1 demonstrates a dense, solitary vitreous opacity that has been localized with dynamic OCT imaging to track its movements and retinal shadowing with the patient's eye movements. Case 2 shows the utility of adjusting the fixation target to monitor the movement of vitreous opacities in real-time. Case 3 exhibits an association between decreased symptom burden and vitreous opacity density after YLV. Image-guided YLV facilitates the localization and confirmation of vitreous opacities. SLO and dynamic OCT of the vitreous can provide a real-time evaluation of floater size, movement, and morphology, to help clinicians target treatment and monitoring of symptomatic floaters.

Identifiants

pubmed: 37402010
doi: 10.1007/s10792-023-02765-4
pii: 10.1007/s10792-023-02765-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3587-3594

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Nature B.V.

Références

Luo J, An X, Kuang Y (2018) Efficacy and safety of yttrium-aluminium garnet (YAG) laser vitreolysis for vitreous floaters. J Int Med Res 46:4465–4471. https://doi.org/10.1177/0300060518794245
doi: 10.1177/0300060518794245 pubmed: 30200800 pmcid: 6259370
Singh IP (2018) Novel OCT application and optimized YAG laser enable visualization and treatment of mid- to posterior vitreous floaters. Ophthal Surg Lasers Imaging Retin 49:806–811. https://doi.org/10.3928/23258160-20181002-10
doi: 10.3928/23258160-20181002-10
Shah CP, Heier JS (2017) YAG laser vitreolysis vs sham YAG vitreolysis for symptomatic vitreous floaters. JAMA Ophthalmol 135:918. https://doi.org/10.1001/jamaophthalmol.2017.2388
doi: 10.1001/jamaophthalmol.2017.2388 pubmed: 28727887 pmcid: 5710539
Sebag J, Yee KMP, Wa CA et al (2014) Vitrectomy for floaters: prospective efficacy analyses and retrospective safety profile. Retina 34:1062–1068. https://doi.org/10.1097/IAE.0000000000000065
doi: 10.1097/IAE.0000000000000065 pubmed: 24296397
Zou H, Liu H, Xu X, Zhang X (2013) The impact of persistent visually disabling vitreous floaters on health status utility values. Qual Life Res 22:1507–1514. https://doi.org/10.1007/s11136-012-0256-x
doi: 10.1007/s11136-012-0256-x pubmed: 23054488
Milston R, Madigan MC, Sebag J (2016) Vitreous floaters: etiology, diagnostics, and management. Surv Ophthalmol 61:211–227. https://doi.org/10.1016/j.survophthal.2015.11.008
doi: 10.1016/j.survophthal.2015.11.008 pubmed: 26679984
Ivanova T, Jalil A, Antoniou Y et al (2016) Vitrectomy for primary symptomatic vitreous opacities: an evidence-based review. Eye 30:645–655. https://doi.org/10.1038/eye.2016.30
doi: 10.1038/eye.2016.30 pubmed: 26939559 pmcid: 4869141
Shaimova VA, Shaimov TB, Ryzhkov PK, et al (2018) Evaluation of YAG-laser vitreolysis effectiveness based on quantitative characterization of vitreous floaters. Vestn Oftal’mologii 134:56. https://doi.org/10.17116/oftalma2018134156-62
Tripathy K (2017) Is Floaterectomy Worth the Risks? Asia-Pacific J Ophthalmol 176:384–386. https://doi.org/10.22608/APO.201738
Sommerville DN (2015) Vitrectomy for vitreous floaters: analysis of the benefits and risks. Curr Opin Ophthalmol 26:173–176. https://doi.org/10.1097/ICU.0000000000000150
doi: 10.1097/ICU.0000000000000150 pubmed: 25784107
Kokavec J, Wu Z, Sherwin JC, et al (2017) Nd: YAG laser vitreolysis versus pars plana vitrectomy for vitreous floaters. Cochrane Database Syst Rev 2017. https://doi.org/10.1002/14651858.CD011676.pub2
Tian J, Zhang J, Yuan G et al (2019) Nd:YAG laser vitreolysis for symptomatic vitreous floaters: application of infrared fundus photography in assessing the treatment efficacy. J Ophthalmol 2019:1–7. https://doi.org/10.1155/2019/8956952
doi: 10.1155/2019/8956952
Nguyen JH, Nguyen-Cuu J, Yu F et al (2019) Assessment of vitreous structure and visual function after neodymium:Yttrium–Aluminum–Garnet laser vitreolysis. Ophthalmology 126:1517–1526. https://doi.org/10.1016/j.ophtha.2019.06.021
doi: 10.1016/j.ophtha.2019.06.021 pubmed: 31471088
Delaney YM, Oyinloye A, Benjamin L (2002) Nd:YAG vitreolysis and pars plana vitrectomy: surgical treatment for vitreous floaters. Eye 16:21–26. https://doi.org/10.1038/sj.eye.6700026
doi: 10.1038/sj.eye.6700026 pubmed: 11913884
Peyman GA (1984) Contact lenses for Nd: Yag application in the vitreous. Retina 4:129–131. https://doi.org/10.1097/00006982-198400420-00012
doi: 10.1097/00006982-198400420-00012 pubmed: 6540469
Su D, Shah CP, Hsu J (2020) Laser vitreolysis for symptomatic floaters is not yet ready for widespread adoption. Surv Ophthalmol 65:589–591. https://doi.org/10.1016/j.survophthal.2020.02.007
doi: 10.1016/j.survophthal.2020.02.007 pubmed: 32135173
Souza CE, Lima LH, Nascimento H et al (2020) Objective assessment of YAG laser vitreolysis in patients with symptomatic vitreous floaters. Int J Retin Vitr 6:1–5. https://doi.org/10.1186/s40942-019-0205-8
doi: 10.1186/s40942-019-0205-8
Serpetopoulos CN, Korakitis RA (1998) An optical explanation of the entoptic phenomenon of “clouds” in posterior vitreous detachment. Ophthalmic Physiol Opt 18:446–451. https://doi.org/10.1016/S0275-5408(98)00018-0
doi: 10.1016/S0275-5408(98)00018-0 pubmed: 10023478
Mamou J, Wa CA, Yee KMP et al (2015) Ultrasound-based quantification of vitreous floaters correlates with contrast sensitivity and quality of life. Investig Ophthalmol Vis Sci 56:1611–1617. https://doi.org/10.1167/iovs.14-15414
doi: 10.1167/iovs.14-15414
Garcia GA, Khoshnevis M, Yee KMP et al (2016) Degradation of contrast sensitivity function following posterior vitreous detachment. Am J Ophthalmol 172:7–12. https://doi.org/10.1016/j.ajo.2016.09.005
doi: 10.1016/j.ajo.2016.09.005 pubmed: 27633841
Garcia GA, Khoshnevis M, Yee KMP et al (2018) The effects of aging vitreous on contrast sensitivity function. Graefe’s Arch Clin Exp Ophthalmol 256:919–925. https://doi.org/10.1007/s00417-018-3957-1
doi: 10.1007/s00417-018-3957-1
Ringel MJ, Tang EM, Tao YK (2021) Advances in multimodal imaging in ophthalmology. Ther Adv Ophthalmol 13:251584142110024. https://doi.org/10.1177/25158414211002400
doi: 10.1177/25158414211002400
Katsanos A, Tsaldari N, Gorgoli K et al (2020) Safety and efficacy of YAG laser vitreolysis for the treatment of vitreous floaters : an overview. Adv Ther. https://doi.org/10.1007/s12325-020-01261-w
doi: 10.1007/s12325-020-01261-w pubmed: 33108623 pmcid: 7854404

Auteurs

Shangjun Jiang (S)

Section of Ophthalmology, Department of Surgery, Cumming School of Medicine, 1403 29 St NW, Calgary, AB, T2N 2T9, Canada. collierjiang@gmail.com.

John Golding (J)

Vitreous Retina Macula Specialists of Toronto, 3280 Bloor Street West, Suite 310, Etobicoke, ON, M8X 2X3, Canada.

Netan Choudhry (N)

Vitreous Retina Macula Specialists of Toronto, 3280 Bloor Street West, Suite 310, Etobicoke, ON, M8X 2X3, Canada. netan.choudhry@vrmto.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH